Back to search

University of Patras

Ανάπτυξη λιποσωμικών μορφών ρελαξίνης-2 και παραγώγων αυτής, για παράταση της διάρκειας δράσης τους

Abstract

dc:description

Nanotechnology in pharmacy is a broad scientific field that has emerged from the convergence of disciplines such as health and pharmaceutical sciences, molecular chemistry, and engineering. It has contributed significantly to the enhancement of the stability of therapeutic agents and their targeted delivery to diseased tissues. Several types of nanoparticles have been proposed for the encapsulation of active substances. At the same time, studies have been conducted on the modification of active molecules with the aim of prolonging their pharmacological action by optimizing their stability in the circulatory system. In the present dissertation, Relaxin-2 (RLX2), a multifunctional hormone of the insulin-like peptide family, was investigated. This peptide exerts beneficial effects on multiple systems, including the brain, kidneys, reproductive system, and the cardiorespiratory system. The aim of this study was the development of liposomal formulations of reduced and oxidized Relaxin-2, as well as a modified form of the reduced peptide achieved through conjugation with the hydrophobic molecule palmitic acid, in order to prolong their duration of action in cells. As a first step, the reduced form of Relaxin-2, conjugated with a fluorescent agent to improve its detectability, was investigated by comparing two encapsulation techniques in liposomal carriers: active loading and the dehydration–rehydration vesicle (DRV) method. It was demonstrated that the latter method achieved enhanced encapsulation efficiency compared to active loading for a specific lipid composition. Subsequently, this method was employed in a new study aimed at identifying the optimal encapsulation across a range of lipid compositions. In addition, the same lipid compositions of the liposomal carriers were examined for prolonged drug retention in release experiments. The studies showed that liposomal carriers containing a negatively charged lipid exhibited higher encapsulation efficiency compared to the other formulations. Furthermore, these carriers displayed a greater percentage of drug retention over a defined study period relative to the other liposomal systems. Subsequently, liposomal formulations of reduced and oxidized Relaxin-2 were compared in terms of optimal biomolecule encapsulation. The formulations exhibiting optimal encapsulation, as well as the free reduced and oxidized Relaxin-2 molecules, were evaluated for their stability in the presence of PBS and 80:20 (FBS:PBS). Finally, with the aim of investigating prolonged cellular activity, a comparison was conducted between the free forms of reduced, oxidized, and palmitoyl Relaxin-2, as well as the corresponding liposomal formulations with the optimal lipid compositions, which were shown to be more stable in the aforementioned media. The presence of a negatively charged lipid confirmed the findings of the previously mentioned studies using RLX2–FITC liposomal formulations, exhibiting a higher encapsulation efficiency. Regarding stability, liposomal carriers of both oxidized and reduced RLX2 showed improved stability compared to the non-encapsulated peptides in the presence of FBS. The biological activity of the free peptides demonstrated higher activity for the reduced form compared to the other two forms. Concerning the biological activity of the two encapsulated forms (reduced and oxidized RLX2) within the same liposomal carriers, the protective effect of encapsulation was highlighted. With respect to palmitoyl RLX2, no substantial difference in activity was observed between the encapsulated and non-encapsulated molecule; however, although the molecule initially exhibited low activity levels, its activity was maintained for a duration of thirty days.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kogkos, Georgios
  • Κόγκος, Γεώργιος

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60662

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kogkos, Georgios; Κόγκος, Γεώργιος. Ανάπτυξη λιποσωμικών μορφών ρελαξίνης-2 και παραγώγων αυτής, για παράταση της διάρκειας δράσης τους. University of Patras, 2025. http://hdl.handle.net/10442/hedi/60662